NCT04186637View on ClinicalTrials.gov

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies

PHASE1TerminatedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

June 2, 2020

Primary Completion Date

November 9, 2022

Study Completion Date

February 28, 2023

Conditions
Advanced Solid TumorLymphoma
Interventions
DRUG

ALPN-202

Multiple dose levels and dose regimens of ALPN-202 will be administered

Trial Locations (10)

3004

Investigational Site (101), Melbourne

Investigational Site (103), Melbourne

6009

Investigational Site (102), Perth

15232

Investigational Site (008), Pittsburgh

40202

Investigational Site (006), Louisville

47905

Investigational Site (007), Lafayette

49546

Investigational Site (001), Grand Rapids

85258

Investigational Site (004), Scottsdale

97213

Investigational Site (009), Portland

06520

Investigational Site (003), New Haven

Sponsors
All Listed Sponsors
lead

Alpine Immune Sciences, Inc.

INDUSTRY

NCT04186637 - An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies | Biotech Hunter | Biotech Hunter